354 related articles for article (PubMed ID: 22989410)
1. Similarities and differences between five European drug reimbursement systems.
Franken M; le Polain M; Cleemput I; Koopmanschap M
Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
[TBL] [Abstract][Full Text] [Related]
2. European drug reimbursement systems' legitimacy: five-country comparison and policy tool.
Cleemput I; Franken M; Koopmanschap M; le Polain M
Int J Technol Assess Health Care; 2012 Oct; 28(4):358-66. PubMed ID: 22980497
[TBL] [Abstract][Full Text] [Related]
3. A comparison of pharmaceutical reimbursement agencies' processes and methods in France and Scotland.
Bending M; Hutton J; McGrath C
Int J Technol Assess Health Care; 2012 Apr; 28(2):187-94. PubMed ID: 22559763
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries.
Franken M; Stolk E; Scharringhausen T; de Boer A; Koopmanschap M
Health Policy; 2015 Feb; 119(2):195-202. PubMed ID: 25456017
[TBL] [Abstract][Full Text] [Related]
5. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.
Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F
Value Health; 2014; 17(1):98-108. PubMed ID: 24438723
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
7. Evaluation on the first 2 years of the positive list system in South Korea.
Park SE; Lim SH; Choi HW; Lee SM; Kim DW; Yim EY; Kim KH; Yi SY
Health Policy; 2012 Jan; 104(1):32-9. PubMed ID: 22001369
[TBL] [Abstract][Full Text] [Related]
8. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
9. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.
Ha D; Choi Y; Kim DU; Chung KH; Lee EK
Clin Ther; 2011 Jul; 33(7):926-32. PubMed ID: 21715008
[TBL] [Abstract][Full Text] [Related]
11. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
[TBL] [Abstract][Full Text] [Related]
12. Role of budget impact in drug reimbursement decisions.
Cohen JP; Stolk E; Niezen M
J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
[TBL] [Abstract][Full Text] [Related]
13. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
Franken M; Koopmanschap M; Steenhoek A
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
[TBL] [Abstract][Full Text] [Related]
14. Drug reimbursement policies in Canada--need for improved access to critical therapies.
LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
[TBL] [Abstract][Full Text] [Related]
15. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
16. Pricing and reimbursement of pharmaceuticals in Italy.
Folino-Gallo P; Montilla S; Bruzzone M; Martini N
Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
[TBL] [Abstract][Full Text] [Related]
17. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
Persson U; Willis M; Odegaard K
Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
[TBL] [Abstract][Full Text] [Related]
18. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
19. Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.
Sandmann FG; Franken MG; Steenhoek A; Koopmanschap MA
Health Policy; 2013 Oct; 112(3):285-96. PubMed ID: 23628483
[TBL] [Abstract][Full Text] [Related]
20. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
Castillo-Laborde C; Silva-Illanes N
Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
